Fig. 1 · Structure

Documents & Downloads

Cangrelor (AR-C69931)

Cat. No. A12843 CAS 163706-06-7
Cangrelor is a potent intravenous adenosine diphosphate-receptor antagonist

In Stock

Publications for Cangrelor

2 publications citing this product

  1. Tasuku SAKAYORI, .et al. , Sysmex Journal International, 2024, Vol.34 No.1
  2. Satoru Koyanagi, .et al. , Nat Commun, 2016, 7: 13102 PMID: 27739425

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Cangrelor (AR-C69931) Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Cangrelor (AR-C69931) from 3 published references. In vivo models include C57BL6 male mice; Apoe −/− mice on C57BL/6 background.

Cangrelor (AR-C69931) In Vitro Studies

Cangrelor was added to the reperfusion perfusate of Langendorff-perfused mouse hearts following global ischaemia. Infarct-size measurements showed no evidence of protection compared with the NaCl vehicle control. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cangrelor During Reperfusion in Isolated Mouse Hearts

Cell-based study · Langendorff perfused mouse heart; Male C57BL6 mice (3–4 months of age, 20–30 g weight) [1]

Langendorff-perfused mouse hearts undergoing global ischaemia received Cangrelor in the perfusate throughout reperfusion. Infarct-size measurements showed no evidence of protection compared with the NaCl vehicle control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
infarct size by triphenyl tetrazolium chloride (TTC) staininginfarct size 39 ± 3 %, 41 ± 3 %, 36 ± 3 % and 44 ± 5 % for control, 20, 200 and 400 nmol/L Cangrelor respectively[1]

Literature-Reported Treatment Conditions

Treatment concentration
20, 200 or 400 nmol/L
Exposure duration
35 min global, normothermic (37.0 ± 0.2 °C) ischaemia and 30 min reperfusion; for the duration of reperfusion
Method
reperfusion perfusate fortified
Vehicle
NaCl vehicle
Co-treatment
Other interventions in this design: global, normothermic (37.0 ± 0.2 °C) ischaemia. Compound effect isolated by the comparison: NaCl vehicle (control) or 20, 200 or 400 nmol/L Cangrelor.
Methods and source locations

Compound reported in the paper: Cangrelor

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Ex-Vivo Mouse Heart Perfusion (S3, S6, S7); Results > Cangrelor is Protective In-Vivo, But Not Ex-Vivo (S45)

infarct size by triphenyl tetrazolium chloride (TTC) staining: infarct size by triphenyl tetrazolium chloride (TTC) staining; comparator: NaCl vehicle (control) — Methods > Ex-Vivo Mouse Heart Perfusion (S7); Results > Cangrelor is Protective In-Vivo, But Not Ex-Vivo (S45)

Cangrelor (AR-C69931) In Vivo Studies

In male ICR mice, hippocampal Cangrelor pretreatment followed by LPS significantly increased target-quadrant time and platform location crossings compared with vehicle plus LPS. In male mice undergoing regional ischaemia and reperfusion, intravenous Cangrelor reduced infarct size compared with saline vehicle. In Apoe-deficient mice undergoing ultrasound-induced plaque rupture, intravenous Cangrelor was associated with more emboli shed from thrombi than in control mice. [2,1,3]

Spatial memory outcomes in mice with LPS-induced cognitive impairment

Animal study · Male Institute of Cancer Research (ICR) mice; LPS-induced cognitive impairment; n = 12 mice/group [2]

Male ICR mice received Cangrelor pretreatment by microinfusion into bilateral hippocampal DG regions before LPS administration. Compared with vehicle plus LPS, Cangrelor plus LPS significantly increased the percentage of time spent in the target quadrant and the number of platform location crossings.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The percentage of total time spent in the target quadrant during the probe trialReported result cangrelor 2.0 μg + LPS; cangrelor 4.0 μg + LPS: pretreatment with cangrelor significantly increased both the percentage of time spent in the target quadrant and the number of platform location crossings compared to the Veh + LPS group[2]

Conditions shared by the study groups

Route
microinfused into bilateral DG regions of the hippocampus
Treatment course
every day for 3 weeks; followed by LPS (0.25 mg/kg, i.p.) or its vehicle was administered for 7 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Cangrelor 2.0 μg; 4.0 μgvehicle plus LPS (Veh + LPS)cangrelor 2.0 μg + LPS; cangrelor 4.0 μg + LPS: pretreatment with cangrelor significantly increased both the percentage of time spent in the target quadrant and the number of platform location crossings compared to the Veh + LPS group[2]
Cangrelor 2.0 μg; 4.0 μg
Model: Male Institute of Cancer Research (ICR) mice; LPS-induced cognitive impairment; n = 12 mice/group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Cangrelor

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animals (S1); Materials and methods > LPS-induced cognitive impairment mouse model > The drug treatment experiment (S25, S30, S34); Results > Inhibition of GPR17 with cangrelor attenuates cognitive impairment induced by LPS in mice (S164, S174); Fig. 3 legend (S292, S301)

The percentage of total time spent in the target quadrant during the probe trial: The percentage of total time spent in the target quadrant during the probe trial; comparator: vehicle plus LPS (Veh + LPS) — Materials and methods > LPS-induced cognitive impairment mouse model > The drug treatment experiment (S25); Results > Inhibition of GPR17 with cangrelor attenuates cognitive impairment induced by LPS in mice (S174); Fig. 3 legend (S301)

Cangrelor 2.0 μg; 4.0 μg · Materials and methods > LPS-induced cognitive impairment mouse model > The drug treatment experiment (S25, S34); Results > Inhibition of GPR17 with cangrelor attenuates cognitive impairment induced by LPS in mice (S174); Fig. 3 legend (S292)

Infarct size following regional ischaemia and reperfusion in mice

Animal study · C57BL6 male mice [1]

Male mice undergoing regional ischaemia and reperfusion received intravenous Cangrelor by bolus infusion followed by continuous infusion during reperfusion. Infarct size was lower with Cangrelor than with the saline vehicle control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
infarct sizeinfarct size 10 min bolus infusion of Cangrelor (60 μg/kg) followed by a continuous infusion of Cangrelor (6 μg/kg/min) upon the onset and for the duration of reperfusion: 28 ± 6 %[1]

Conditions shared by the study groups

Route
intravenous
Treatment course
Ten minutes prior to the onset of reperfusion; 10 min bolus infusion; continuous infusion; upon the onset and for the duration of reperfusion; 35 min injurious regional ischaemia, followed by 2 h reperfusion
Vehicle
normal saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Cangrelor 60 μg/kg; 6 μg/kg/minvehicle (normal saline)52 ± 5 % in control hearts versus 28 ± 6 % with cangrelor and 25 ± 1 % for ischaemic preconditioning, p < 0.05[1]
Cangrelor 60 μg/kg; 6 μg/kg/min
Model: C57BL6 male mice
Methods and source locations

Compound reported in the paper: Cangrelor

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > In-Vivo Mouse Ischaemia/Reperfusion (S8, S13, S16, S17, S18); Results > Cangrelor is Protective In-Vivo, But Not Ex-Vivo (S42); Fig. 1 legend (S54)

infarct size: infarct size; comparator: vehicle (normal saline) — Methods > In-Vivo Mouse Ischaemia/Reperfusion (S17, S18); Results > Cangrelor is Protective In-Vivo, But Not Ex-Vivo (S42)

Cangrelor 60 μg/kg; 6 μg/kg/min · Methods > In-Vivo Mouse Ischaemia/Reperfusion (S16, S17); Results > Cangrelor is Protective In-Vivo, But Not Ex-Vivo (S42)

Embolus shedding following plaque rupture in mice

Animal study · Apoe −/− mice on C57BL/6 background [3]

Apoe-deficient mice received continuous intravenous Cangrelor beginning before ultrasound treatment. With Cangrelor present, more fluorescent emboli were shed from thrombi after plaque rupture than in control mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Number of fluorescent emboli shed during 3 min after plaque ruptureemboli shed cangrelor continuously infused at 3 µg/kg/min: 4–5 fold more emboli[3]

Conditions shared by the study groups

Route
intravenously
Treatment course
continuously infused; started at 15 min before ultrasound treatment
Vehicle
5% mannitol in saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Cangrelor 3 µg/kg/minvehicle solutionWith ticagrelor or cangrelor present, 4–5 fold more emboli were shed from thrombi in comparison to control mice[3]
Cangrelor 3 µg/kg/min
Model: Apoe −/− mice on C57BL/6 background
Methods and source locations

Compound reported in the paper: Cangrelor

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals (S9, S10); Materials and Methods > In vivo plaque rupture and measurement of thrombus formation (S15, S20); Materials and Methods > In vivo administration of P2Y12 antagonist and blood collection (S30); Results > Inhibition of mouse P2Y12 receptors causes unstable thrombus formation after rupture of an atherosclerotic plaque (S70, S82); Figure 1 legend (S129, S131, S141)

Number of fluorescent emboli shed during 3 min after plaque rupture: Number of fluorescent emboli shed during 3 min after plaque rupture; comparator: vehicle solution — Results > Inhibition of mouse P2Y12 receptors causes unstable thrombus formation after rupture of an atherosclerotic plaque (S82); Figure 1 legend (S131, S141)

Cangrelor 3 µg/kg/min · Materials and Methods > In vivo administration of P2Y12 antagonist and blood collection (S30); Results > Inhibition of mouse P2Y12 receptors causes unstable thrombus formation after rupture of an atherosclerotic plaque (S82); Figure 1 legend (S131)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 163706-06-7
Formula C17H25Cl2F3N5O12P3S2
Molecular Weight 776.36
Synonyms AR-C 69931
SMILES
CSCCNC1=NC(=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O)SCCC(F)(F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Cangrelor (AR-C69931) Research References

  1. [1] Bell RM, Sivaraman V, Kunuthur SP, et al. Cardioprotective Properties of the Platelet P2Y12 Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood. Cardiovasc Drugs Ther (2015). PMID: 26179955 DOI: 10.1007/s10557-015-6609-2 Source material
  2. [2] Liang Y, Kang X, Zhang H, et al. Knockdown and inhibition of hippocampal GPR17 attenuates lipopolysaccharide-induced cognitive impairment in mice. J Neuroinflammation (2023). PMID: 37990234 DOI: 10.1186/s12974-023-02958-9 Source material
  3. [3] Nergiz-Unal R, Cosemans JM, Feijge MA, et al. Stabilizing role of platelet P2Y(12) receptors in shear-dependent thrombus formation on ruptured plaques. PLoS One (2010). PMID: 20405028 DOI: 10.1371/journal.pone.0010130 Source material

Publications

2 publications citing this product

  1. Tasuku SAKAYORI, .et al. , Sysmex Journal International, 2024, Vol.34 No.1
  2. Satoru Koyanagi, .et al. , Nat Commun, 2016, 7: 13102 PMID: 27739425

Added to your cart

View Cart Checkout
Loading...